We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 141

In a Unanimous Vote, the Opioid Crisis Response Act of 2018 Makes it Onto the Legislative Calendar
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • June 6 2018

As previously discussed in our post from September 2017, the push for a response to the opioid crisis is gaining momentum. Enter the “Opioid Crisis


Materiality Part III: It Is Not Enough That The Government Could Refuse PaymentThe Question Is Whether The Government Would Refuse Payment
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • April 16 2018

In Part II of our series, we discussed government knowledge. When the government knows of a claim’s falsity, but nevertheless pays the claim, the


New DOJ Guidance Policy Limits Use of Guidance Documents in Federal Civil Actions
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • February 20 2018

On January 25, 2018, Associate Attorney General Rachel Brand issued a memorandum on behalf of the U.S. Department of Justice (DOJ) (the “Brand


Materiality Part II: Government Knowledge
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • January 3 2018

This is the second in a five-part series on how U.S. district courts and courts of appeal have applied the materiality standard set forth in Universal


Metallizing Forfeiture Post-Helsinn
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • June 13 2017

In Helsinn Healthcare S.A. V. Teva Pharmaceuticals USA, Inc., the Federal Circuit had its first opportunity to address the impact of the


New York AG Takes Enforcement Action Against Heart Monitoring Apps: Murmurs of Concern are Heard in mHealth App World
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • April 5 2017

In a move sure to cause murmurs in the large and growing mobile health application industry, the Office of New York Attorney General Eric Schneiderman


Proposed New FDA Labeling Rules Would Result in Increased Generic Drug Product Liability Claims
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • October 14 2016

After several years of delay, FDA announced this summer that it expects to publish new rules in April 2017 that will permit generic drug companies to


Forget About Vermont!: Congress Passes GMO “Labeling” Legislation
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • July 19 2016

On July 14, 2016, the House of Representatives passed S.764 creating a National Bioengineered Food Standard. Importantly for food manufacturers and


En Banc: Federal Circuit Provides Guidance on Application of On-Sale Bar to Contract Manufacturers
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • July 13 2016

Pharmaceutical and biotech companies breathed a sigh of relief Monday when the Federal Circuit unanimously ruled in a precedential opinion that the


En Banc: Federal Circuit Provides Guidance on Application of On-Sale Bar to Contract Manufacturers
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • July 13 2016

Pharmaceutical and biotech companies breathed a sigh of relief Monday when the Federal Circuit unanimously ruled in a precedential opinion that the